Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.

Alessandra MangiaR SarliR GamberiniA PigaG CenderelloV PiazzollaR SantoroV CarusoA QuartaR GangaM CopettiG Forni

Published in: Alimentary pharmacology & therapeutics (2017)

In conclusion, SOF/LDV for 12 weeks provides simple, highly effective and safe Peg-IFN/RBV-free treatment for HCV GT1/4 thalassaemia patients. EUDRACT number 2015-002401-1.

Keyphrases

hepatitis c virus
clinical trial
end stage renal disease
open label
ejection fraction
double blind
human immunodeficiency virus
study protocol
peritoneal dialysis
chronic kidney disease
cardiac surgery
immune response
prognostic factors
drug delivery
phase ii
acute kidney injury
sickle cell disease